title: Could advanced drug delivery systems be the future in cardiovascular revascularization medicine?
abstract: Acute myocardial infarction, stroke and pulmonary embolism required a prompt revascularization to restore the normal blood flow as soon as possible. Fibrinolytic treatment has gradually become both dated and underused in the treatment of acute myocardial infarction, after the wide diffusion of cathlab and percutaneous transluminal coronary angioplasty. Conversely, the use of systemic thrombolysis remained a benchmark in the treatment of both ischemic stroke and massive pulmonary embolism. In daily clinical practice, the use of thrombolytic agents is often limited by absolute and/or relative contraindications and possible adverse events after the drug administration, as intracranial and/or extracranial bleeding events. To minimize these problems, during the last years, the introduction of nanotechnology in the field of cardiovascular revascularization medicine has created several fascinating results. In the present article, we describe these recent findings and their possible implications in future clinical practice.
authors.affiliation: 1 Section of Internal and Cardiopulmonary Medicine, Department of Medical Science, University of Ferrara, Ferrara, Italy.|2 Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Zuin
authors.affiliation: 3 Section of Adult Congenital and Adult Heart Disease, Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Rigatelli
authors.affiliation: 4 Department of Cardiac Surgery, University of Verona, Verona, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Faggian
authors.affiliation: 5 Department of Neurosciences, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: L'Erario
authors.affiliation: 5 Department of Neurosciences, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Chinaglia
authors.affiliation: 2 Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.
authors.forename: Loris
authors.initials: L
authors.lastname: Roncon
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002548:Cerebral Revascularization / Q000009:adverse effects / Q000379:methods*; D004337:Drug Carriers; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000379:methods*; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D009204:Myocardial Revascularization / Q000009:adverse effects / Q000379:methods*; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*
chemical_list: D004337:Drug Carriers; D005343:Fibrinolytic Agents
keywords: Revascularisation; nanoparticles; thrombolytic therapy